Neurotech International Limited
NTI.ASXHealth Care
A clinical-stage biopharmaceutical development company focused on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164
Market Data
$0.012
+0.1%$15.8M
-100000.0x
$-0.004
0.00%
-0.4%
Latest Earnings
Appendix 4D & Half Year Report
26 February 2026
Neurotech International reported a 91% reduction in losses to $0.7M for H1 FY2026, primarily driven by a $4.7M R&D grant income that offset $4.2M in R&D expenses. The company raised $4M in funding and received HREC approval to commence its pivotal Phase 3 autism spectrum disorder study, marking significant clinical progress. Key points: Dramatic 91% reduction in losses from $7.4M to $0.7M driven by $4.7M R&D grant income; Received HREC approval to commence pivotal Beyond Harmony Phase 3 ASD clinical study; Successfully raised ~$4M in funding to advance clinical programs
Recent Announcements
Ceasing to be a substantial holder
MAYBANK SECURITIES PTE. LTD ceased to be a substantial holder (4.52%).
Appendix 4D & Half Year Report
Neurotech International reported a 91% reduction in losses to $0.7M for H1 FY2026, primarily driven by a $4.7M R&D grant income that offset $4.2M in R&D expenses. The company raised $4M in funding and received HREC approval to commence its pivotal Phase 3 autism spectrum disorder study, marking significant clinical progress. Key points: Dramatic 91% reduction in losses from $7.4M to $0.7M driven by $4.7M R&D grant income; Received HREC approval to commence pivotal Beyond Harmony Phase 3 ASD clinical study; Successfully raised ~$4M in funding to advance clinical programs
Get real-time alerts for NTI
Receive AI-powered earnings summaries and instant notifications when Neurotech International Limited releases results.
Register Free